Cite
Enhanced antitumour efficacy of functionalized doxorubicin plus schisandrin B co-delivery liposomes via inhibiting epithelial-mesenchymal transition.
MLA
Cai, Fu-Yi, et al. “Enhanced Antitumour Efficacy of Functionalized Doxorubicin plus Schisandrin B Co-Delivery Liposomes via Inhibiting Epithelial-Mesenchymal Transition.” Journal of Liposome Research, vol. 31, no. 2, June 2021, pp. 113–29. EBSCOhost, https://doi.org/10.1080/08982104.2020.1745831.
APA
Cai, F.-Y., Yao, X.-M., Jing, M., Kong, L., Liu, J.-J., Fu, M., Liu, X.-Z., Zhang, L., He, S.-Y., Li, X.-T., & Ju, R.-J. (2021). Enhanced antitumour efficacy of functionalized doxorubicin plus schisandrin B co-delivery liposomes via inhibiting epithelial-mesenchymal transition. Journal of Liposome Research, 31(2), 113–129. https://doi.org/10.1080/08982104.2020.1745831
Chicago
Cai, Fu-Yi, Xue-Min Yao, Ming Jing, Liang Kong, Jing-Jing Liu, Min Fu, Xin-Ze Liu, et al. 2021. “Enhanced Antitumour Efficacy of Functionalized Doxorubicin plus Schisandrin B Co-Delivery Liposomes via Inhibiting Epithelial-Mesenchymal Transition.” Journal of Liposome Research 31 (2): 113–29. doi:10.1080/08982104.2020.1745831.